Precision Medicine in Oncology®

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in March 2026 spanning tumor types.

The FDA cleared relacorilant plus nab-paclitaxel in ovarian cancer, the primary end point of the SENTRY trial in myelofibrosis was met, and more.

The ETOP ADEPPT trial met its primary end point with a 31% 12-week ORR with adagrasib in patients at least 70 years old with an ECOG PS of 0 or 1.

The FDA has cleared nivolumab/AVD for classical Hodgkin lymphoma, accepted a bezuclastinib NDA for review in nonadvanced systemic mastocytosis, and more.

The EC approved an indication extension for niraparib and abiraterone acetate dual-action tablets plus prednisone/prednisolone with ADT in BRCA1/2-mutated mHSPC.

Zovegalisib plus fulvestrant drove responses in HR-positive, HER2-negative, PIK3CA-mutant advanced breast cancer

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in February 2026 spanning tumor types.

The top 5 OncLive TV videos of the week cover insights in lung cancer, renal cell carcinoma, prostate cancer, head and neck cancer, and multiple myeloma.

The FDA has granted accelerated approval to zongertinib in HER2 TKD–mutated NSCLC, full approval to an encorafenib combination in BRAF V600E+ mCRC, and more.

The top 5 OncLive TV videos of the week cover insights in genitourinary cancers, hematologic malignancies, colorectal cancer, and sarcoma.

The FDA approved a frontline acalabrutinib regimen in CLL/SLL and a simplified dosing schedule for Rybrevant Faspro in EGFR+ NSCLC and will review NDAs in PCNSL and breast cancer.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in January 2025 spanning tumor types.

The top 5 OncLive TV videos of the week cover insights in acute lymphoblastic leukemia, breast cancer, urothelial cancer, ovarian cancer, and follicular lymphoma.

The FDA granted priority review to Dato-DXd in triple-negative breast cancer, accepted an NDA for zanzalintinib plus atezolizumab in mCRC, and more.

The FDA has approved Darzalex Faspro plus VRd for select multiple myeloma and several applications are under regulatory review in lung and GI cancers.

EMA CHMP backs niraparib plus abiraterone with ADT for BRCA1/2-mutant mHSPC, supported by data from the AMPLITUDE study.

Xiuning Le, MD, PhD, discusses the FDA approval of sevabertinib for pretreated, advanced, nonsquamous NSCLC with tumors harboring HER2 TKD mutations.

A rusfertide NDA for polycythemia vera has been submitted to the FDA, a tafasitamab combination boosts PFS over R-CHOP in DLBCL, and more.

Here is your Q1 2026 preview spotlighting 5 FDA decisions to watch, including upcoming PDUFAs for tabelecleucel, pembrolizumab, and more.

The FDA cleared narsoplimab for TA-TMA, an NDA seeking approval of bezuclastinib in nonadvanced systemic mastocytosis has been submitted, and more.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in December 2025 spanning tumor types.

The top 5 OncLive TV videos of the week cover insights in ALL, breast cancer, lung cancer, and pancreatic cancer.

The top 5 OncLive TV videos of the week cover insights in myeloma, AML, Ph-positive ALL, pediatric low-grade glioma, and nonadvanced systemic mastocytosis.

The FDA approved T-DXd plus pertuzumab in HER2+ breast cancer, subcutaneous amivantamab in EGFR+ NSCLC, and rucaparib in BRCA-mutated mCRPC.

The FDA has granted regular approval to rucaparib (Rubraca) for BRCA mutation–associated metastatic castration-resistant prostate cancer.